Appeal No. 1997-2368
Application 08/158,782
Claim 1 is illustrative of the subject matter on appeal and reads as follows:
1. A method of targeting a therapeutic agent to a focus of infection, which
comprises parenterally injecting a patient infected with a pathogen with an effective
amount of a polyspecific antibody-therapeutic agent conjugate;
wherein said conjugate comprises an immunoreactive composite of a plurality of
chemically-linked antibodies or antibody fragments which specifically binds to a plurality of
accessible epitopes on a single species of pathogen or of an antigen shed by said
pathogen or resulting from the fragmentation or destruction of said pathogen and which is
accreted at said focus of infection,
wherein said polyspecific antibody conjugate further comprises a chemically bound
therapeutic agent for treating said infection.
The references relied upon by the examiner are:
Rodwell et al. (Rodwell) 4,671,958 June 9, 1987
Goldenberg ('525) 5,120,525 June 9, 1992
Goldenberg ('567) 5,332,567 July 26, 1994
Holder et al. (Holder), “Biosynthesis and Processing of a Plasmodium Falciparum
Schizont Antigen Recognized by Immune Serum and a Monoclonal Antibody,”
J. Exp. Med., Vol. 156, pp. 1528-538 (Nov. 1982)
Brennan et al. (Brennan), "Preparation of Bispecific Antibodies by Chemical
Recombination of Monoclonal Immunoglobulin G Fragments,” Science, Vol. 229,
1
pp. 81-83 (July 1985)
GROUNDS OF RECORD
Claims 1, 3-6, 8-10, 19, 20, 24, 25, 39-44, and 46-48 stand rejected under
35 U.S.C. § 103. As evidence of obviousness, the examiner relies on Rodwell, Holder,
Goldenberg ('525), and Brennan.
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 Next
Last modified: November 3, 2007